MAP2K1 and neoplasm: Interestingly, combined inhibition of MEK1/2(with Trametinib [T]) plus autophagy (with chloroquine [CQ] or hydroxychloroquine [HCQ]) demonstrated striking anti-tumor effects in preclinical models and in a patient.